Andrew S Young

Author:

Andrew McLaren Young

ISBN #:

0300023847

Author:

Andrew McLaren Young

ISBN #:

0709159420

Author:

Andrew McLaren Young

ISBN #:

0709160887

Author:

Andrew McLaren Young

ISBN #:

0950080004

Author:

Andrew J. Young

ISBN #:

0382099230

Author:

Andrew J. Young

ISBN #:

0382099249

Author:

Andrew J. Young

ISBN #:

0382099257

Author:

Andrew J. Young

ISBN #:

0382240650

US Patent:

6602694, Aug 5, 2003

Filed:

Jun 27, 2001

Appl. No.:

09/743847

Inventors:

Keith Albrandt - San Diego CA
Kevin Beaumont - San Diego CA
Andrew A. Young - San Diego CA

Assignee:

Amylin Pharmaceuticals, Inc - San Diego CA

International Classification:

C12N 900

US Classification:

435183, 530350, 530333

Abstract:

A novel uncoupling protein, which we have designated UCP-4, that is expressed in various tissues, including brain, heart, pancreas, and muscle tissue, and nucleic acid molecules which encode for said novel protein, are described. Methods of screening for compounds that regulate the expression and the activity of UCP-4 are described, as well as methods of treating diseases or conditions in which the regulation of thermogenesis or respiratory ATP synthesis is desired. Such conditions include obesity, diabetes, malignant hyperthermia, and fever. The construction of cell lines that express UCP-4 is also described.

US Patent:

6608029, Aug 19, 2003

Filed:

May 22, 2000

Appl. No.:

09/576062

Inventors:

Orville G. Kolterman - Poway CA
Andrew A. Young - Alpine CA
Timothy J. Rink - La Jolla CA
Kathleen Ann Keating Brown - Wake Forest NC

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 3810

US Classification:

514 12, 514 13, 514 21

Abstract:

Methods for treating conditions associated with elevated, inappropriate or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an amylin agonist alone or in conjunction with other anti-gastric emptying agents. Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are also described.

US Patent:

6703359, Mar 9, 2004

Filed:

Sep 22, 2000

Appl. No.:

09/622105

Inventors:

Andrew A. Young - San Diego CA
Will Vine - Poway CA
Nigel R. A. Beeley - Solana Beach CA
Kathryn Prickett - San Diego CA

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A01N 3718

US Classification:

514 2, 514866, 530324

Abstract:

Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia,such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

US Patent:

6858576, Feb 22, 2005

Filed:

Aug 8, 1997

Appl. No.:

08/908867

Inventors:

Andrew A. Young - San Diego CA, US
Bronislava Gedulin - San Diego CA, US
Nigel Robert Arnold Beeley - Solana Beach CA, US
Kathryn S. Prickett - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K038/00
A61K038/16
A61K038/17
A61K038/26
C07K005/00

US Classification:

514 2, 514 12, 514 21, 530300, 530308

Abstract:

Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other anti-gastric emptying agents.

US Patent:

6872700, Mar 29, 2005

Filed:

Jan 14, 2000

Appl. No.:

09/889331

Inventors:

Andrew A. Young - La Jolla CA, US
Bronislava Gedulin - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K038/02
A61K038/26

US Classification:

514 2, 530308, 530322, 530 33, 530402, 530421, 4242781

Abstract:

Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucagon or suppressing glucagon secretion.

US Patent:

6902744, Jun 7, 2005

Filed:

Jan 14, 2000

Appl. No.:

09/889330

Inventors:

Orville G. Kolterman - Poway CA, US
Andrew A. Young - La Jolla CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K009/14

US Classification:

424489, 4242781, 514 2, 514 3, 514 4, 514 12, 514866, 530300

Abstract:

Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

US Patent:

6924264, Aug 2, 2005

Filed:

Apr 28, 2000

Appl. No.:

09/561226

Inventors:

Kathryn S. Prickett - San Diego CA, US
Andrew A. Young - San Diego CA, US

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K038/22

US Classification:

514 2, 530308, 530322, 530402, 530412

Abstract:

Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonist analogs, compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake.

US Patent:

7101853, Sep 5, 2006

Filed:

May 6, 1997

Appl. No.:

08/851965

Inventors:

Andrew A. Young - San Diego CA, US
Bronislava Gedulin - San Diego CA, US
Gareth Wyn Beynon - Brightwell-cum Sotwell, GB

Assignee:

Amylin Pharmaceuticals, Inc. - San Diego CA

International Classification:

A61K 38/00

US Classification:

514 14, 514 12, 514 13

Abstract:

Methods for treating or preventing gastritis or gastric injury are disclosed, comprising administering a therapeutically effective amount of an amylin or an amylin agonist. Methods are also disclosed for the treatment of pain, fever, inflammation, arthritis, hypercoagulability, or other conditions for which a non-steroidal anti-inflammatory drug would be indicated, comprising administering an amylin or amylin agonist in conjunction with administering a therapeutically effective amount of a non-steroidal anti-inflammatory agent. Pharmaceutical compositions comprising an amylin or amylin agonist and a non-steroidal anti-inflammatory drug are also disclosed.